OOIR: Observatory of International Research

Papers

(The H4-Index of Current Atherosclerosis Reports is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Revascularization Options for Left Main Disease: What Clinicians Need to Know	88
Are Clinicians Aggressive Enough in Treating Diabetes-Related Hyperlipidemia in Youth?	84
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions	81
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?	78
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management	71
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment	63
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis	59
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes	57
Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management	56
Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?	56
Ambient Air Pollution and Atherosclerosis: Recent Updates	54
Watermelon and l-Citrulline in Cardio-Metabolic Health: Review of the Evidence 2000–2020	52
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?	50
The Effects of FABP4 on Cardiovascular Disease in the Aging Population	50
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women	47
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond	43
DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm	43
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice	42
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators	41
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease	40
The Emerging Specialty of Cardio-Rheumatology	39
Inflammation in the Peri-ACS Period: Ready for Prime Time?	38
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?	36
Correction to: Beta‑blockers for Atherosclerosis Prevention: a Missed Opportunity?	36
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention	34

GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?	33
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review	33
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease	33
Percutaneous Coronary Interventions in Women	32
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women	31
RNA Silencing in the Management of Dyslipidemias	31
Myeloid Cells in Abdominal Aortic Aneurysm	31